enteritis after radiotherapy and / or chemotherapy
conditions after surgical operations in the gastrointestinal tract
disturbances in the composition of the intestinal microbiota, including during and after antibiotic therapy
nutritional deficiencies (insufficient supply of dietary fiber, low-residual diet)
Innovative, patented 3rd generation technology implemented in ButiSan®
easy-to-swallow product – high butyrate content in single capsule (up to 500mg per capsule)
best on market release profile: 60% of butyrate ion delivered into large intestine
Butyrate from 1 capsule delivered to large intestine [mg]
Compet 1 = 26,9
Compet 2 = 37,5
Compet 2 = 55,8
Butisan® = 101,2
* ButiSan® 150mg NaBut/capsule
ButiRect®
Medical device ButiRect® is intendedned for rectal use in order to:
support the regeneration of erosions, injuries, and other defects within the rectal mucosa,
reduce painful symptoms of defecation coming from damages of the rectal epithelia typical for the inflammation course,
support the regeneration of anal canal tissues after surgical procedures and/or radiotherapy,
restore the physiological functionality of rectal mucosa.
In ButiRect® concentration of sodium butyrate may reach the value of 0.91 mmol / ml
a concentration several times higher than those obtained in the recent clinical trials that used rectal enemas, far sufficient to obtain the expected local therapeutic effect.
Divertix®
Divertix® enteral capsules are intended for the dietary management:
in symptomatic uncomplicated diverticular disease (clinical trial)
in inflammatory bowel diseases
in order to support the restoration of the natural composition of the intestinal microflora and to improve the physiological state of the colonic mucosa.
